<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262700</url>
  </required_header>
  <id_info>
    <org_study_id>FILE-PROT-005120</org_study_id>
    <nct_id>NCT04262700</nct_id>
  </id_info>
  <brief_title>Customer Outcomes &amp; Value Experiencing A New Monitoring Technology</brief_title>
  <acronym>CONVERT</acronym>
  <official_title>Customer Outcomes &amp; Value Experiencing A New Monitoring Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeScan Scotland Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LifeScan Scotland Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether novel insight features in new Blood Glucose Monitoring System (BGMs)
      can improve glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 7, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A1c change from baseline after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>A1c change from baseline after 12 weeks in subjects using new BGMS compared to subjects' pre-study glycemic control</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention 01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects use new LifeScan provided BGMS for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifeScan's new BGMS</intervention_name>
    <description>LifeScan new Blood Glucose Monitoring System (BGMS)</description>
    <arm_group_label>Intervention 01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Summary:

          -  Diagnosed with Type 1 diabetes mellitus or Type 2 diabetes mellitus for â‰¥ 3 month
             prior to screening

          -  Currently performing self-monitoring of blood glucose (SMBG) at home for diabetes
             management decisions

          -  Willingness to notify the study staff if they become pregnant during the study

          -  Willing to sign an informed consent

        Exclusion Criteria Summary:

          -  Currently using a continuous or flash glucose monitoring

          -  Currently pregnant or planning pregnancy within duration of study or breast feeding;
             subjects who become pregnant during the study will be withdrawn.

          -  Conflict of Interest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mike Grady</last_name>
    <phone>01463 721000</phone>
    <email>MGRADY@lifescan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kirsty Macleod</last_name>
    <email>kmacleod@lifescan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Sudworth</last_name>
    </contact>
    <investigator>
      <last_name>Dr. Nicola Zammitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highland Diabetes Institute</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MacFarlane, MD</last_name>
    </contact>
    <investigator>
      <last_name>David MacFarlane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Device being used in the study is CE marked and will be used as intended therefore risk is minimal. What? Individual participant data that underlie the results reported in publications, after deidentification (text, tables, figures, and appendices).
When? Beginning 9 months and ending 36 months following article publication. With whom? Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. For individual participant data meta-analysis. By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available from our archive but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found by reaching out to the study contact listed. What other documents will be available?Abbreviated CSR may be provided upon request and assessment by the company.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Up to 12 months post study completion.</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

